Literature DB >> 18285760

Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme.

David Schiff1, Benjamin Purow.   

Abstract

Entities:  

Year:  2008        PMID： 18285760     DOI： 10.1038/ncponc1077

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  5 in total

Review 1.  Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

Authors:  Terri S Armstrong; Patrick Y Wen; Mark R Gilbert; David Schiff
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

2.  Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.

Authors:  Matthew Crocker; Sue Ashley; Ian Giddings; Vladimir Petrik; Anthea Hardcastle; Wynne Aherne; Andy Pearson; B Anthony Bell; Stergios Zacharoulis; Marios C Papadopoulos
Journal:  Neuro Oncol       Date:  2010-12-16       Impact factor: 12.300

3.  Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Authors:  Benjamin M Ellingson; Hyun J Kim; Davis C Woodworth; Whitney B Pope; Jonathan N Cloughesy; Robert J Harris; Albert Lai; Phioanh L Nghiemphu; Timothy F Cloughesy
Journal:  Radiology       Date:  2013-11-27       Impact factor: 11.105

Review 4.  Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment.

Authors:  Daniela Rizzo; Antonio Ruggiero; Maurizio Martini; Valentina Rizzo; Palma Maurizi; Riccardo Riccardi
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

Review 5.  Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials.

Authors:  Frank Lieberman
Journal:  F1000Res       Date:  2017-10-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.